Camlin Fine Sciences working capital

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
203.90×203.90×223.40×215.90×159.48×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
74.26×74.26×67.17×66.72×66.11×
174.58×174.58×150.82×122.45×129.42×
103.58×103.58×139.75×160.17×96.17×
7.16×6.63×4.94×6.06×5.74×
0.79×0.79×0.84×0.80×0.99×
3.49×3.49×−0.17×−1.33×1.28×
0.77×0.77×0.13×1.88×0.25×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CAMLINFINE₹82.32

Camlin Fine Sciences Limited

· Chemicals
₹ CrorePeersCLEANDEEPAKNTRBAYERCROPTIRUMALCHMATULSHKPAUSHAKLTDANURASMcap ₹1,581 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)159.48215.90223.40203.90203.90
Receivable Days (DSO)66.1166.7267.1774.2674.26
Payable Days (DPO)129.42122.45150.82174.58174.58
Cash Conversion Cycle (days)96.17160.17139.75103.58103.58
Working Capital Turnover5.746.064.946.637.16
Asset Turnover0.990.800.840.790.79
Cash Conversion (CFO/Net Income)1.28-1.33-0.173.493.49
CFO/EBITDA0.251.880.130.770.77
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.